This is a preview of subscription content, log in via an institution to check access.
References
Chiesi Farmaceutici. Chiesi’s new treatment for neuropathic pain proceeds to proof-of-concept study. Media Release: 3 Jun 2003. Available from URL: http://www.chiesigroup.com/
Chiesi Farmaceutici. CHF 3381: non-confidential product profile. Company Communication: [8 pages], 13 May 2003
Rondelli I, Puccini P, Marchetti S. Interspecies comparison of in vitro and in vivo metabolism of CHF 3381. European Journal of Pharmaceutical Sciences 8: (Additional abstracts), May 1999
Villetti G, Bregola G, Bassani F, et al. Preclinical evaluation of CHF3381 as a novel antiepileptic agent. Neuropharmacology 40: 866, Jun 2001
Barbieri M, Bregola G, Buzzi A, et al. Mechanisms of action of CHF3381 in the forebrain. British Journal of Pharmacology 139: 1333–1341, No. 7, Aug 2003
Zucchini S, Buzzi A, Bergamaschi M, et al. Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate recep tor antagonist. Neuroreport 13: 2071–2074, 15 Nov 2002
Tarral A, Dostert P, Guillevic Y, et al. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel n-methyl-d- aspartate antagonist, after single oral doses in healthy subjects. Journal of Clinical Pharmacology 43: 901–911, No. 8, Aug 2003
Rights and permissions
About this article
Cite this article
CHF 3381. Drugs R&D 5, 28–30 (2004). https://doi.org/10.2165/00126839-200405010-00005
Published:
Issue date:
DOI: https://doi.org/10.2165/00126839-200405010-00005